SCHEDULE 13G: OrbiMed Entities Disclose Passive Stake in ADC Therapeutics SA

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed a Schedule 13G, disclosing their passive beneficial ownership of 6.2% of ADC Therapeutics SA's common shares as of December 31, 2024.

Summary

• OrbiMed Advisors LLC and OrbiMed Capital LLC, both Delaware-based investment advisers, have filed a Schedule 13G regarding their beneficial ownership in ADC Therapeutics SA.
• The filing indicates that as of December 31, 2024, OrbiMed Advisors LLC beneficially owned 2,530,638 common shares, representing 2.6% of the class, with shared voting and dispositive power.
• OrbiMed Capital LLC beneficially owned 3,437,813 common shares, representing 3.6% of the class, with sole voting and dispositive power.
• Collectively, the reporting persons, OrbiMed Advisors LLC and OrbiMed Capital LLC, hold an aggregate of 6.2% of ADC Therapeutics SA's Common Shares.
• The shares are held on behalf of other persons, and the filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain performance data or forward-looking statements that would typically influence sentiment.

Management Comments

• Carl L. Gordon, Member of OrbiMed Capital LLC and OrbiMed Advisors LLC, certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing is a routine disclosure of passive beneficial ownership by investment advisers in a publicly traded company. It does not provide specific insights into broader industry trends but reflects an investment firm's portfolio allocation within the healthcare or biotechnology sector, where ADC Therapeutics SA operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes, which can offer insights into institutional investor interest in the company.

Key Dates

Keywords

ADC Therapeutics SA, OrbiMed Advisors LLC, OrbiMed Capital LLC, Schedule 13G, Beneficial Ownership, Common Shares, Investment Adviser, SEC Filing, Passive Investment